{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:32:03Z","timestamp":1761093123389,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.urolonc.2021.04.016","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T18:41:54Z","timestamp":1626115314000},"page":"521-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology"],"prefix":"10.1016","volume":"39","author":[{"given":"Tanya B.","family":"Dorff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brock","family":"O'Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin R.","family":"Loughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Dall'Era","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.04.016_bib0001","unstructured":"Stephenson JA, Wiley AL, Current techniques in three-dimensional C simulation and radiation treatment planning. Oncology 1995; 9(11):1225-32"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0002","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.1994.12.4.689","article-title":"Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer","volume":"4","author":"Moore","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0003","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0004","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jnci\/djg040","article-title":"Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control","volume":"95","author":"Weir","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0006","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":". Cancer risks in BRCA2 mutation carriers","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst (Bethesda)"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 carriers: results from the initial screening round of the IMPACT study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0009","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr Follow-up of the european randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0011","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0012","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US preventive services task force recommendation statement","volume":"319","author":"Force","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0013","first-page":"1473","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"Siegel","year":"2020"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0014","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","article-title":"Genomic markers in prostate cancer decision making","volume":"73","author":"Cucchiara","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0015","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0016","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.ju.0000107247.81471.06","article-title":"The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry","volume":"171","author":"Cooperberg","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0017","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0018","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0019","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/01.ju.0000095025.03331.c6","article-title":"Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE)","volume":"170","author":"Cooperberg","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.eururo.2012.05.072","article-title":"Active surveillance for prostate cancer: a systematic review of the literature","volume":"62","author":"Dall'Era","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0021","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active surveillance for the management of localized prostate cancer (cancer care ontario guideline): american society of clinical oncology clinical practice guideline endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0022","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/pros.2990040506","article-title":"Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations","volume":"4","author":"Walsh","year":"1983","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0023","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0090-4295(02)01852-6","article-title":"Technique of da Vinci robot-assisted anatomic radical prostatectomy","volume":"60","author":"Tewari","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0024","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2016.01.044","article-title":"Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database","volume":"70","author":"Leow","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0025","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2021.04.016_bib0026","doi-asserted-by":"crossref","first-page":"414","DOI":"10.6004\/jnccn.2013.0056","article-title":"Radiation therapy modalities in prostate cancer","volume":"11","author":"Pugh","year":"2013","journal-title":"Review J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0027","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"34","key":"10.1016\/j.urolonc.2021.04.016_bib0028","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01097","volume":"36","author":"Morgan","year":"2018","journal-title":"J Clin Oncol."},{"issue":"11","key":"10.1016\/j.urolonc.2021.04.016_bib0029","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"\u201cIntensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.\u201d","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.04.016_bib0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.urolonc.2021.04.016_bib0031","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1053-4296(97)80046-X","article-title":"20 years of progress in radiation oncology: prostate cancer","volume":"7","author":"Hanks","year":"1997","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0032","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0033","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"EORTC Radiation Oncology Group. Genito-Urinary Tract Cancer Group Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0034","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.urolonc.2021.04.016_bib0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III","volume":"74","author":"Nabid","year":"2018","journal-title":"Trial.Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0036","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0037","doi-asserted-by":"crossref","unstructured":"Sundahl N, Tree A, Parker C. The emerging role of local therapy in metastatic prostate cancer. 2020;22(1):2.","DOI":"10.1007\/s11912-020-0868-1"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0038","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1073\/pnas.79.4.1273","article-title":"Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone","volume":"79","author":"Redding","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0039","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-roup phase III study in patients iwht prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0040","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased Survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0041","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: A novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0042","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Mollanen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0043","first-page":"314","article-title":"Androgen receptor gene amplification: a possible mechanism for androgen deprivation therapy failure in prostate cancer","volume":"57","author":"Koivisto","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0044","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0045","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression to castration resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0046","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"deBono","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0047","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0048","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0049","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic castration sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0051","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0052","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0053","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from southwest oncology group trials 9346 and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0054","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0055","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising Prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0056","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0057","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0058","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial","volume":"376","author":"deBono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0059","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"deWit","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0061","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0062","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"New Eng J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0063","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.04.016_bib0064","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.1995.03520260051032","article-title":"Quality-of-life outcomes in men treated for localized prostate cancer","volume":"273","author":"Litwin","year":"1995","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.urolonc.2021.04.016_bib0065","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.urolonc.2021.04.016_bib0066","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2021.04.016_bib0067","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2021.04.016_bib0068","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.urolonc.2021.04.016_bib0069","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bju.13582","article-title":"ProtecT Study group. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life","volume":"118","author":"Lane","year":"2016","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2021.04.016_bib0070","first-page":"239","article-title":"Decision aids for localized prostate cancer treatment choice: Systematic review and meta-analysis","volume":"65","author":"Violette","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0071","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.urpr.2015.10.006","article-title":"AUA white paper on implementation of shared decision making into urological practice","volume":"3","author":"Makarov","year":"2016","journal-title":"Urol Pract"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0072","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0073","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0074","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0075","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and Cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0076","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0077","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]- PSMA-617 radionuclide treatment in patients with metastatic castration resistant prostate cancer (LuPSMA trial): a single-centre, single-arm phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0078","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): a randomized phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0079","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer (The ORIOLE phase 2 randomized clinical trial)","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0080","doi-asserted-by":"crossref","first-page":"s507","DOI":"10.1016\/j.annonc.2020.08.869","article-title":"609O Results from a phase I study of AMG 160, a half-life extended HLE, PSMA-targted bispecific T-cell engager (BiTE) immune therapy for metastatic castratino-resistant prostate cancer (mCRPC)","volume":"31","author":"Tran","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2021.04.016_bib0081","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921001757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921001757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:21:01Z","timestamp":1761042061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921001757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1078143921001757"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}